GLP-1 and Weight Loss: Understanding, Efficacy, and Challenges

The topic of GLP-1 for weight loss has emerged at the intersection of physiology, nutrition, and the management of overweight and obesity. Part of the interest stems from a simple fact: weight gain is not just a matter of willpower. The biological signals that regulate hunger, satiety, food reward, blood sugar, and the use of energy substrates strongly influence appetite and the ability to maintain a calorie deficit over time.

In this context, GLP-1 (Glucagon-Like Peptide-1) is often presented as the satiety hormone. GLP-1 acts on several axes simultaneously (intestines, pancreas, brain, stomach), and its effects combine with other hormones and neurotransmitters involved in weight regulation. GLP-1 approaches for weight loss can therefore be relevant for certain profiles, but they do not replace a healthy lifestyle, professional guidance, or personalization. The challenge is twofold: first, understanding how GLP-1 influences the reduction of cravings, appetite, and food intake; and second, knowing what results are observed, at what pace, for whom it is most effective, and what precautions are necessary.

GLP-1 (Glucagon-Like Peptide-1) is a hormone naturally produced by the intestine, involved in the regulation of blood sugar and appetite. Often referred to as the satiety hormone, it plays a key role in the mechanisms associated with GLP-1 weight loss by influencing hunger, digestion, and satiety signals.

GLP-1 is a peptide produced primarily by specialized cells in the intestine (L-cells) in response to the arrival of nutrients after a meal. It belongs to the incretin system—intestinal hormones that participate in postprandial metabolic adaptation. GLP-1 has a unique characteristic: its circulating half-life is short because it is rapidly degraded by an enzyme (DPP-4). This explains why, in a weight loss strategy using GLP-1, molecules known as GLP-1 analogues or GLP-1 agonists are designed to last longer and provide prolonged activation of the GLP-1 receptor.

Beyond the terminology, remembering the basics helps: GLP-1 is a biological signal that tells the body that a meal is in progress or has just taken place. It helps curb the desire to keep eating, improve blood sugar management, and coordinate digestion.

GLP-1 acts on several complementary mechanisms. First, it strengthens insulin secretion in a glucose-dependent manner, meaning the effect is particularly relevant when blood sugar is high after a meal. Second, it modulates glucagon secretion (the hormone that promotes glucose release from the liver), contributing to better blood sugar stability. Third, it acts on digestive motility, notably by slowing down gastric emptying, which prolongs the feeling of fullness.

Finally—and this is central to weight loss—GLP-1 acts via the gut-brain axis: it sends signals that contribute to satiation (ending the meal) and satiety (the interval between meals). This dimension explains part of the reduction in cravings reported with GLP-1 receptor activation.

The relationship between blood sugar and appetite is bidirectional. Rapid variations in blood sugar can influence hunger levels in some people, while meals very high in simple sugars can encourage a cycle of craving-consumption-craving. GLP-1, by improving glycemic control and slowing gastric emptying, tends to smooth out the postprandial response. This smoothing isn't "magic," but it can facilitate the management of internal signals: fewer spikes, fewer dips, and sometimes a better ability to stop at the right moment.

For people with insulin resistance, postprandial regulation can be more difficult, with a tendency to store more and feel hungry more quickly. In a GLP-1 and weight loss approach, the theoretical interest is twofold: helping to better manage the glycemic signal and reducing the intensity of the food drive. This does not replace diet quality, but it can make changes more sustainable.

The link between GLP-1 and weight loss is based on several biological mechanisms that directly influence appetite, satiety, and digestion. By modulating hunger signals and slowing gastric emptying, GLP-1 helps naturally reduce food intake as part of a sustainable weight loss approach.

Talking about weight loss often means talking about hunger control. GLP-1 receptor activation acts as an amplifier of satiation signals: the meal "counts for more" in the brain. Practically, portion sizes may decrease, food thoughts may occupy less mental space, and reduced cravings may become more accessible for some individuals.

It is useful to distinguish satiation from satiety. Satiation refers to when you stop eating. Satiety refers to the time before hunger returns. GLP-1 can contribute to both: by promoting the end of a meal on one hand, and by extending the "full tank" sensation through slower digestion on the other. This combination explains why GLP-1 is described as a satiety hormone, even though the reality involves multiple hormones (CCK, PYY, leptin, ghrelin, etc.).

Gastric emptying refers to the transfer of stomach contents into the intestine. When this is slower, the feeling of fullness lasts longer, and the urge to eat again can be delayed. GLP-1 physiologically participates in this slowing, and pharmacological activation of the GLP-1 receptor can accentuate this phenomenon, especially at the beginning.

Practically, this also explains certain digestive side effects: if the stomach empties more slowly, very large, very fatty, or rushed meals can become uncomfortable. A GLP-1 and weight loss approach that is compatible with digestive comfort therefore often favors smaller portions, mindful chewing, and structured meals rather than extreme restriction.

Food intake is not solely dictated by physiological hunger. Stress, fatigue, the environment, sleep, taste rewards, and habits all play a major role. The value of GLP-1 and weight loss strategies is also behavioral: by reducing the intensity of the hunger signal and the frequency of cravings, they can facilitate choices more consistent with a goal of sustainable weight loss.

However, biology does not replace learning. Even when hunger decreases, habits such as mindless snacking, emotional eating, skipping meals, and compensating in the evening can persist. A truly sustainable approach therefore combines understanding hunger signals, organizing meals, protein and fiber intake, and managing triggers (stress, lack of sleep). This is often where the difference between transient loss and sustainable weight loss is determined.

GLP-1-based medications are used in certain situations to support weight loss by acting on the mechanisms of appetite and satiety. They are based on specific molecules, called GLP-1 agonists, which mimic the action of this hormone to promote more effective regulation of food intake.

GLP-1 agonists are molecules that activate the GLP-1 receptor for a prolonged period. They are designed to mimic the effects of physiological GLP-1, but with a duration of action compatible with daily or weekly administration, depending on the specific molecule. This prolonged action is one of the reasons for the efficacy observed in several clinical trials on weight loss.

It is essential to remember that these treatments are medications, with precise indications, dosage progression, and medical supervision. They should not be confused with dietary supplements, and they are not intended as part of an "express program" approach.

Natural GLP-1 has a short half-life. GLP-1 analogues and, more broadly, GLP-1 agonists are modified to resist degradation, remain in the body longer, and activate the receptor in a sustained manner. This difference in pharmacokinetics changes the intensity and duration of effects on appetite, satiety, and gastric emptying.

This also explains a reality often underestimated: the body adapts. The first few weeks may be marked by a clear drop in appetite, followed by a plateau, and then stabilization. Long-term efficacy then depends on incorporating a realistic lifestyle. Clinically, major studies systematically include support (dietary advice, physical activity), which serves as a reminder that weight loss is not an effortless process.

Prescriptions are generally part of the management of overweight and obesity when eligibility criteria are met (BMI, comorbidities, failure of well-conducted lifestyle and dietary approaches, etc.) and when the benefit-risk ratio is judged to be favorable. Recommendations for access may vary by country and healthcare system; for example, agencies such as NICE in the UK regulate the use of semaglutide within structured and multidisciplinary programs.

In a responsible reading of the subject related to weight loss, it is important to understand that the goal is not to accelerate weight loss. The goal is to improve the weight and metabolic trajectory within a framework where safety, tolerance, adherence, and the prevention of weight regain are taken into account.

The GLP-1 weight loss approach is not limited to a hormonal mechanism, but is part of a broader strategy incorporating diet, physical activity, and lifestyle habits. For lasting results, GLP-1 should be viewed as a support tool, to complement a consistent and structured lifestyle.

GLP-1 can help reduce appetite. A weight loss strategy using GLP-1 is more robust when it is supported by a structured, sufficiently satiating diet that is compatible with social life. The central pillar remains energy balance: a moderate, sustainable caloric deficit that does not rely on the total exclusion of foods. Demonizing food creates frustration, encourages binge eating, and increases the risk of weight regain.

Physiologically, meals rich in protein and fiber support satiety. Minimally processed foods, moderate-glycemic index carbohydrates, and high-quality fats contribute to better stability. The goal is not perfection, but the repetition of useful choices most of the time.

Morosil®, a Moro blood orange extract standardized in polyphenols, is sometimes mentioned as support in a weight loss process. Unlike GLP-1 agonists, it does not act directly on appetite or satiety, but is instead part of an approach to supporting metabolism and body composition. It should be considered as a complementary lever, integrated into a structured diet and a consistent lifestyle.

Physical activity plays several roles in a GLP-1 and weight loss approach. It helps preserve lean mass during weight loss, improves insulin sensitivity, supports cardiometabolic health, and contributes to long-term maintenance. Here again, the logic is not extreme: regular progress (walking, strength training, mobility) is often more effective than spikes of intensity that are impossible to maintain.

An important point concerns fatigue: if appetite decreases significantly, it can be tempting to eat too little, which depletes energy and reduces the desire to move. However, an excessive drop in intake can compromise consistency. A coherent weight loss strategy therefore aims to maintain sufficient food intake to support activity and recovery, while maintaining a reasonable caloric deficit.

The key question is this: is the GLP-1 and weight loss approach a temporary crutch or a support tool integrated into a global strategy? Trial data shows that efficacy is maximized when accompanied by lifestyle changes.

GLP-1 can reduce biological friction: less hunger, less snacking, more control. But durability depends on built skills: planning meals, managing triggers, improving sleep quality, moving enough, and staying hydrated. Sleep is often the great forgotten factor, even though nocturnal hormonal regulation influences hunger, recovery, and stress management. Similarly, hydration is a simple but structuring variable, especially when digestive side effects exist.

Finally, the approach must remain realistic: an extreme program does not build a trajectory. A sustainable strategy, even a slow one, almost always wins in the long term, particularly by reducing the risk of weight regain.

• STEP 1 Trial (semaglutide 2.4 mg) - NEJM, "Once-Weekly Semaglutide in Adults with Overweight or Obesity".
• Liraglutide 3.0 mg trial - NEJM, "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management".
• SURMOUNT-1 trial (tirzepatide) - NEJM, "Tirzepatide Once Weekly for the Treatment of Obesity".
• Review of GLP-1 mechanisms (appetite, satiety, gastric emptying) - Trends in Endocrinology & Metabolism.
• Review of gut-brain axis and food intake control - "Intestinal GLP-1 effects on food intake…"